LETTER

Multidrug-resistant tuberculosis: resistance rates to first and reserve antituberculosis drugs in the UK in 2008/9 and the role of rapid molecular tests for drug resistance

At the Health Protection Agency National Mycobacterium Reference Laboratory (HPA NMRL) between January 2008 and December 2009, we evaluated in patients with multidrug-resistant tuberculosis (MDRTB; isolates resistant to rifampicin and isoniazid) the rate of resistance to other first-line drugs (ethambutol and pyrazinamide) and to reserve drugs and the role of rapid molecular tests for rifampicin (and MDRTB) resistance. MDRTB isolates resistant to rifampicin and isoniazid were additionally resistant to one reserve drug, ie, only 34 isolates (67%) were sensitive to all reserve drugs. In the remaining 56 isolates (52%), resistance to rifampicin and isoniazid was combined with resistance to another first-line drug. In the 112 MDRTB cases, 107 (96%) patients had a complete DST profile for all 11 drugs tested, and 87 (78%) isolates were initially identified as MDRTB by ‘fastrack’.

Fifty-one of the 107 isolates (48%) were resistant to rifampicin and isoniazid alone of the first-line drugs (table 1, group 1); 17 (33%) were additionally resistant to one reserve drug, ie, only 34 isolates (67%) were sensitive to all reserve drugs. In the remaining 56 isolates (52%), resistance to rifampicin and isoniazid was combined with resistance to another first-line drug (table 1, group 2), and 54 of these (61%) were additionally resistant to a reserve drug; 22 isolates (39%) were sensitive to all reserve drugs. Almost half (48%) of all MDRTB isolates were resistant to at least one reserve drug and 21% were resistant to all four first-line drugs.

Our results show multidrug-resistant isolates with resistance to one or more of the remaining first-line drugs increases the likelihood of resistance to reserve drugs. In table 1, the rate of resistance to any second-line drug was significantly greater in group 2 (61%) than in group 1 (33%) (Fisher’s exact test p = 0.0065). Our findings justify a policy of using the ‘fastrack’ approach and, when rifampicin resistance has been detected and a culture obtained, of setting up DST to all first and reserve drugs immediately and simultaneously (rather than the conventional approach of DST for reserve drugs only when MDRTB is detected phenotypically). The NMRL has recently added a similar test for resistance to isoniazid and the introduction of genotypic tests for XDRRTB would be highly desirable. This policy would greatly accelerate the return of DST results to relevant clinics, reducing the time for the instigation of appropriate management, helping to reduce any increasing prevalence of MDRTB.

Acknowledgements The authors owe grateful thanks to all staff of the NMRL for their expertise and unfailing help and to all staff of other microbiology laboratories involved in the culture and submission of samples to the NMRL.

S L Mitchell, N Seoudi, D C S Hutchinson, F A Drobniewski

1National Mycobacterium Reference Laboratory, Barts and the London, Queen Mary’s School of Medicine and Dentistry, London, UK; 2Institute of Dentistry, Barts and the London, Queen Mary’s School of Medicine and Dentistry, London, UK; 3Correspondence to Dr F A Drobniewski, National Mycobacterium Reference Laboratory, Barts and the London, Queen Mary’s School of Medicine and Dentistry, London, UK; f.drobniewski@gmail.ac.uk

Competing interests None.

Contributors SLM was responsible for the drug sensitivity tests. FAD was responsible for policy development and is the guarantor. DCSH and NS developed the database for assessing the drug resistance patterns in MDRTB cases. All authors participated in the study design, had full access to all of the data and take full responsibility for the integrity and interpretation of the results and writing of the manuscript. All authors approved the final manuscript.

Provenance and peer review Not commissioned; externally peer reviewed.

Accepted 19 August 2010

Thorax 2010; 65:1. doi:10.1136/thx.2010.148866

REFERENCES


Multidrug-resistant tuberculosis: resistance rates to first and reserve antituberculosis drugs in the UK in 2008/9 and the role of rapid molecular tests for drug resistance

S L Mitchell, N Seoudi, D C S Hutchison and F A Drobniewski

Thorax published online September 29, 2010

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2010/09/29/thx.2010.148866

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2010/08/19/thx.2010.148866.DC1

References
This article cites 3 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/early/2010/09/29/thx.2010.148866#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/